{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Biopharma EHS Podcast Episode No. 16","description":"In this podcast, Dean M. Calhoun, CIH and Joe Nieusma, Ph.D. of Affygility Solutions discuss Category 4 and Category 5 Potent Compounds - Understanding the Risks.\nItems covered include:\n\nReview of the last podcast\nWhat factors go into determining an active pharmaceutical ingredients as a Category 4 or Category 5 potent compound\nWe provide examples of Category 4 and Category 5 potent compounds\nReview upcoming events and happenings related to environmental, health and safety in the biotechnology, pharmaceutical, and medical device industry.\n\nIf you have any questions please contact Affygility Solutions at 303-884-3028 or visit the Affygility Solutions website.","author_name":"Biopharma EHS","author_url":"https:\/\/affygility.coom","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1591738\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1591738"}